Koss Olinger Consulting LLC raised its stake in MiMedx Group, Inc (NASDAQ:MDXG - Free Report) by 605.4% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 73,092 shares of the company's stock after buying an additional 62,730 shares during the quarter. Koss Olinger Consulting LLC's holdings in MiMedx Group were worth $555,000 at the end of the most recent quarter.
Several other large investors also recently added to or reduced their stakes in MDXG. First Light Asset Management LLC purchased a new stake in MiMedx Group in the 4th quarter valued at $32,168,000. JPMorgan Chase & Co. grew its holdings in MiMedx Group by 133.1% in the 4th quarter. JPMorgan Chase & Co. now owns 693,106 shares of the company's stock valued at $6,668,000 after buying an additional 395,739 shares in the last quarter. Meros Investment Management LP purchased a new stake in MiMedx Group in the 4th quarter valued at $3,801,000. Renaissance Technologies LLC grew its holdings in shares of MiMedx Group by 18.4% during the 4th quarter. Renaissance Technologies LLC now owns 1,804,557 shares of the company's stock worth $17,360,000 after purchasing an additional 280,327 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in shares of MiMedx Group by 15.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,802,364 shares of the company's stock worth $17,338,000 after purchasing an additional 238,075 shares during the period. 79.15% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on the company. Cantor Fitzgerald increased their price target on MiMedx Group from $11.00 to $12.00 and gave the stock an "overweight" rating in a report on Thursday, July 31st. Wall Street Zen upgraded MiMedx Group from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 2nd.
Check Out Our Latest Stock Analysis on MDXG
MiMedx Group Price Performance
MDXG opened at $7.02 on Friday. The stock's 50-day moving average price is $6.49 and its 200 day moving average price is $7.19. MiMedx Group, Inc has a 12-month low of $5.47 and a 12-month high of $10.14. The company has a current ratio of 4.39, a quick ratio of 3.90 and a debt-to-equity ratio of 0.08. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of 33.43 and a beta of 1.79.
MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.10 EPS for the quarter, beating analysts' consensus estimates of $0.06 by $0.04. MiMedx Group had a return on equity of 23.03% and a net margin of 8.84%. The company had revenue of $98.61 million during the quarter, compared to analysts' expectations of $90.79 million. As a group, sell-side analysts expect that MiMedx Group, Inc will post 0.3 earnings per share for the current year.
About MiMedx Group
(
Free Report)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
See Also
Want to see what other hedge funds are holding MDXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MiMedx Group, Inc (NASDAQ:MDXG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MiMedx Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.
While MiMedx Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.